Table 1.
Select baseline characteristics of RWE rheumatoid arthritis patients initiating tofacitinib or tumor necrosis factor inhibitors after propensity score fine stratification weighting
| Optum | MarketScan* | Medicare | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Tofacitinib (N=3,761) | TNFI (N=24,688) | SD (%) | Tofacitinib (N=5,298) | TNFI (N=28,727) | SD (%) | Tofacitinib (N=3,782) | TNFI (N=35,816) | SD (%) |
| Demographics | |||||||||
| Age; mean (std) | 56.8 (12.5) | 57.1 (13.2) | −2.6 | 54.7 (11.5) | 55.0 (12.0) | −1.9 | 72.1 (5.6) | 72.2 (5.6) | −1.3 |
| Female Gender; n (%) | 3,043 (80.9) | 20,046 (81.2) | −0.7 | 4,333 (81.8) | 23,503 (81.8) | −0.1 | 3,134 (82.9) | 29,819 (83.3) | −1.0 |
| White race; n (%) | 2,395 (63.7) | 15,691 (63.6) | 0.3 | - | - | - | 3,026 (80.0) | 28,449 (79.4) | 1.4 |
| Black race; n (%) | 412 (11.0) | 2,737 (11.1) | −0.4 | - | - | - | 410 (10.8) | 4,051 (11.3) | −1.5 |
| Asian race; n (%) | 103 (2.7) | 643 (2.6) | 0.8 | - | - | - | 85 (2.2) | 810 (2.3) | −0.1 |
| Hispanic race; n (%) | 471 (12.5) | 3,127 (12.7) | −0.4 | - | - | - | 126 (3.3) | 1224 (3.4) | −0.5 |
| RA related variables | |||||||||
| Number of unique bDMARDs; mean (std) | 1.6 (0.7) | 1.6 (0.7) | 2.4 | 1.8 (0.8) | 1.8 (0.8) | 1.6 | 1.6 (0.7) | 1.6 (0.7) | 2.2 |
| Non-biologic DMARDs | |||||||||
| Number of distinct csDMARDs | 1.0 (0.8) | 1.0 (0.8) | 0.3 | 1.0 (0.8) | 1.0 (0.8) | 1.8 | 1.1 (0.8) | 1.1 (0.8) | 0.8 |
| Any csDMARD use; n (%) | 2,723 (72.4) | 17,851 (72.3) | 0.2 | 3,989 (75.3) | 21,451 (74.7) | 1.4 | 2,889 (76.4) | 27,253 (76.1) | 0.7 |
| Methotrexate; n (%) | 1,731 (46.0) | 11,244 (45.5) | 1.0 | 2,722 (51.4) | 14,582 (50.8) | 1.2 | 1,954 (51.7) | 18,239 (50.9) | 1.5 |
| Hydroxychloroquine; n (%) | 933 (24.8) | 6,143 (24.9) | −0.2 | 1,254 (23.7) | 6,639 (23.1) | 1.3 | 950 (25.1) | 8,915 (24.9) | 0.5 |
| Leflunomide; n (%) | 799 (21.2) | 5,273 (21.4) | −0.3 | 1,065 (20.1) | 5,756 (20.0) | 0.2 | 828 (21.9) | 7,935 (22.2) | −0.6 |
| Sulfasalazine; n (%) | 388 (10.3) | 2,558 (10.4) | −0.1 | 491 (9.3) | 2,604 (9.1) | 0.7 | 418 (11.1) | 3,988 (11.1) | −0.3 |
| Glucocorticoid use | |||||||||
| Prior use of oral glucocorticoids (365 days); n (%) | 2,814 (74.8) | 18,489 (74.9) | −0.2 | 3,896 (73.5) | 21,185 (73.7) | −0.5 | 2,846 (75.3) | 26,944 (75.2) | 0.1 |
| Recent use of Oral Glucocorticoids (60 days); n (%) (60 days) |
1,898 (50.5) | 12,458 (50.5) | 0.0 | 2,625 (49.5) | 14,274 (49.7) | −0.3 | 2,115 (55.9) | 20,072 (56.0) | −0.2 |
| Cumulative dose of oral steroids in mg; mean (std) | 934.5 (1,485.5) | 935.6 (5,973.1) | 0.0 | 1,952.8 (25,666.3) | 2,094 (26,335.2) | −0.5 | 1,024.5 (1,195.2) |
1,019.6 (1,279.5) |
0.4 |
| CVD Risk Factors | |||||||||
| Obesity; n (%) | 882 (23.5) | 5,876 (23.8) | −0.8 | 810 (15.3) | 4392 (15.3) | 0.0 | 581 (15.4) | 5,446 (15.2) | 0.4 |
| Smoking; n (%) | 749 (19.9) | 4,925 (20.0) | −0.1 | 465 (8.8) | 2,566 (8.9) | −0.6 | 972 (25.7) | 9,180 (25.6) | 0.2 |
| Atrial Fibrillation; n (%) | 154 (4.1) | 1,038 (4.2) | −0.6 | 140 (2.6) | 752 (2.6) | 0.1 | 397 (10.5) | 3,723 (10.4) | 0.3 |
| Coronary artery disease; n (%) | 381 (10.1) | 2,564 (10.4) | −0.8 | 425 (8.0) | 2,394 (8.3) | −1.1 | 904 (23.9) | 8,477 (23.7) | 0.5 |
| Type 2 diabetes mellitus; n (%) | 805 (21.4) | 5,353 (21.7) | −0.7 | 835 (15.8) | 4,563 (15.9) | −0.3 | 1,162 (30.7) | 10,918 (30.5) | 0.5 |
| Heart failure; n (%) | 192 (5.1) | 1,324 (5.4) | −1.2 | 175 (3.3) | 960 (3.3) | −0.2 | 450 (11.9) | 4,267 (11.9) | 0.0 |
| Hypertension; n (%) | 1,966 (52.3) | 13,075 (53.0) | −1.4 | 2,355 (44.5) | 12,922 (45.0) | −1.1 | 3,110 (82.2) | 29,417 (82.1) | 0.3 |
| Hyperlipidemia; n (%) | 1,619 (43.0) | 10,706 (43.4) | −0.6 | 2,002 (37.8) | 10,937 (38.1) | −0.6 | 2,569 (67.9) | 24,187 (67.5) | 0.8 |
| Stroke or transient ischemic attack; n (%) | 92 (2.4) | 605 (2.5) | 0.0 | 113 (2.1) | 620 (2.2) | −0.2 | 134 (3.5) | 1,255 (3.5) | 0.2 |
| Peripheral vascular disease; n (%) | 163 (4.3) | 1,103 (4.5) | −0.6 | 141 (2.7) | 776 (2.7) | −0.3 | 442 (11.7) | 4,166 (11.6) | 0.2 |
| Venous thromboembolism; n (%) | 102 (2.7) | 699 (2.8) | −0.7 | 141 (2.7) | 765 (2.7) | 0.0 | 103 (2.7) | 996 (2.8) | −0.4 |
| Other comorbidities | |||||||||
| Chronic liver disease; n (%) | 273 (7.3) | 1,792 (7.3) | 0.0 | 315 (5.9) | 1,696 (5.9) | 0.2 | 317 (8.4) | 2,985 (8.3) | 0.2 |
| Chronic kidney disease (Stage 3+); n (%) | 212 (5.6) | 1,428 (5.8) | −0.6 | 168 (3.2) | 926 (3.2) | −0.3 | 442 (11.7) | 4,207 (11.7) | −0.2 |
| COPD; n (%) | 599 (15.9) | 3,992 (16.2) | −0.7 | 629 (11.9) | 3,454 (12.0) | −0.5 | 1,041 (27.5) | 9,955 (27.8) | −0.6 |
| Inflammatory bowel disease; n (%) | 63 (1.7) | 415 (1.7) | 0.0 | 68 (1.3) | 353 (1.2) | 0.5 | 50 (1.3) | 461 (1.3) | 0.3 |
| Psoriasis; n (%) | 170 (4.5) | 1,100 (4.5) | 0.3 | 169 (3.2) | 885 (3.1) | 0.6 | 119 (3.1) | 1,028 (2.9) | 1.6 |
| Cancer (excluding NMSC); n (%) | 484 (12.9) | 3,267 (13.2) | −1.1 | 692 (13.1) | 3,783 (13.2) | −0.3 | 789 (20.9) | 7,438 (20.8) | 0.2 |
| Combined Comorbidity Index; mean (std) | 1.2 (2.0) | 1.2 (2.0) | −0.8 | 0.7 (1.5) | 0.7 (1.5) | −0.7 | 1.8 (2.4) | 1.9 (2.4) | −0.4 |
| Frailty score; mean (std) | 0.2 (0.0) | 0.2 (0.0) | −0.8 | 0.1 (0.0) | 0.1 (0.0) | −1.5 | 0.2 (0.0) | 0.2 (0.0) | 0.0 |
-Full Tables describing all patient characteristics before and after PS-weighting are provided in the Supplementary Material.
-Abbreviation: bDMARD-biological disease modifying anti-rheumatic drugs, COPD- Chronic obstructive pulmonary disease, CRP-C-reactive protein, csDMARDs-conventional synthetic disease modifying anti-rheumatic drugs, NMSC-Non-melanoma skin cancer, RA-rheumatoid arthritis, SD- standardized difference, std-standard deviation, TNFI- tumor necrosis factor inhibitors
*
Data for race is not available in MarketScan